Skip to main content
RFL
NYSE Life Sciences

Rafael Files FDA NDA for NPC Drug Despite Phase 3 Miss

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Real Estate Services Stocks · Real Estate
Sentiment info
Positive
Importance info
8
Price
$1.14
Mkt Cap
$62.934M
52W Low
$1.12
52W High
$3.96
52W Position info
1.8% above low
Off High info
71% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

RFL is trading near its 52-week low of $1.12 (1.8% above the low) on light trading volume (0.2× avg).

Summary

Rafael Holdings submitted an NDA to the FDA for remibetadex (Trappsol Cyclo) in Niemann-Pick Disease Type C, roughly a month after the Phase 3 TransportNPC study missed its primary endpoint. The filing leans on secondary data: a 71% relative slowing of disease progression in the prespecified background-therapy subgroup (p=0.046) and an 85% reduction in mortality risk in infantile-onset patients versus registry controls (p=0.044). Serious adverse events were more frequent on drug than placebo, 35.9% versus 16.7%. The FDA has 60 days to decide whether to accept the application and grant Priority Review; Orphan Drug, Fast Track and Rare Pediatric Disease designations are already in place, and approval would make the company eligible for a Priority Review Voucher — a potential source of non-dilutive cash for a company with a modest market value and a stock near its 52-week low. The binary risk is filing acceptance and eventual approval on data that failed its primary endpoint.

At the time of this announcement, RFL was trading at $1.14 on NYSE in the Life Sciences sector, with a market capitalization of approximately $62.9M. The 52-week trading range was $1.12 to $3.96. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

RFL - Latest Insights

RFL
Oct 29, 2026, 11:35 AM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $1.20
Real-time Price: $1.09 info
Change: -$0.105 (-9%) info
Market Cap: $57.937M info
RFL
Oct 29, 2026, 8:16 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.14
Real-time Price: $1.09 info
Change: -$0.050 (-4%) info
Market Cap: $57.937M info
RFL
Sep 30, 2026, 7:23 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.32
Real-time Price: $1.09 info
Change: -$0.230 (-17%) info
Market Cap: $57.937M info
RFL
Sep 30, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $1.24
Real-time Price: $1.09 info
Change: -$0.150 (-12%) info
Market Cap: $57.937M info
RFL
Jul 08, 2026, 4:45 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.57
Real-time Price: $1.09 info
Change: -$1.48 (-58%) info
Market Cap: $57.937M info